Electroacupuncture as Adjunctive Therapy for Organ Dysfunction Among Chinese ICU Patients with Sepsis: Study Protocol for a Randomized Clinical Trial

Abstract

Background

Sepsis is a dysregulated response of the host to infection that can lead to life-threatening organ dysfunction and remains a leading cause of mortality. Early recovery of impaired organ function is crucial for the outcomes of sepsis. Electroacupuncture (EA) is a promising adjunctive therapy for sepsis, but no study has focused on the efficacy of EA for organ dysfunction. This study aimed to investigate the efficacy and safety of EA in improving organ dysfunction among intensive care unit (ICU) patients with sepsis.

Methods

In this single-center, randomized, sham-controlled clinical trial, an adaptive sample size of 154–500 patients diagnosed with sepsis will be included. Eligible patients will be randomly assigned to receive EA or sham EA treatment at a 1:1 ratio using block randomization. Patients in the two groups will receive 6 consecutive sessions of 30-min EA or sham EA treatment, with the initial acupuncture treatment being completed within 24 h after randomization. The primary outcome is the change in the total score of the Sepsis-Related Sequential Organ Failure Assessment (SOFA) on day 7 after randomization compared with baseline. Secondary outcomes include changes in the SOFA score and related serological outcomes, mortality, ICU-free days, hospital-free days and organ support-free days from baseline to day 28. Statistical analyses will be performed on a full analysis set (FAS) and a per-protocol set (PPS).

Discussion

We expect the findings of this trial to provide evidence that the use of EA as an adjunctive therapy to ICU treatment can promote the recovery of organ function and other outcomes in sepsis patients.

Trial Registration

ClinicalTrials.gov identifier: NCT06666946. Registered on 28 October 2024.

Keywords

Sepsis / Electroacupuncture / Organ dysfunction / Inflammation / Randomized controlled trial

References

[1] Singer M, Deutschman CS, Seymour CW, et al. . The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA., 2016, 315(8): 801-810

[2] Rudd KE, Johnson SC, Agesa KM, et al. . Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet., 2020, 395(10219): 200-211

[3] Angus DC, Linde-Zwirble WT, Lidicker J, et al. . Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med., 2001, 29(7): 1303-1310

[4] Weng L, Xu Y, Yin P, et al. . National incidence and mortality of hospitalized sepsis in China. Crit Care., 2023, 27(1): 84

[5] Xie J, Wang H, Kang Y, et al. . The epidemiology of sepsis in Chinese ICUs: a national cross-sectional survey. Crit Care Med., 2020, 48(3): e209-e218

[6] Reinhart K, Daniels R, Kissoon N, et al. . Recognizing sepsis as a global health priority: a WHO resolution. N Engl J Med., 2017, 377(5): 414-417

[7] van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immunity., 2021, 54(11): 2450-2464

[8] Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ., 2016, 353: i1585

[9] Dellinger RP, Bagshaw SM, Antonelli M, et al. . Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA., 2018, 320(14): 1455-1463

[10] Fowler AA3rd, Truwit JD, Hite RD, et al. . Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA., 2019, 322(13): 1261-1270

[11] Fujii T, Luethi N, Young PJ, et al. . Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the VITAMINS randomized clinical trial. JAMA., 2020, 323(5): 423-431

[12] Lyu QQ, Zheng RQ, Chen QH, et al. . Early administration of hydrocortisone, vitamin C, and thiamine in adult patients with septic shock: a randomized controlled clinical trial. Crit Care., 2022, 26(1): 295

[13] Madsen MB, Hjortrup PB, Hansen MB, et al. . Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med., 2017, 43(11): 1585-1593

[14] Moskowitz A, Huang DT, Hou PC, et al. . Effect of ascorbic acid, corticosteroids, and thiamine on organ injury in septic shock: the ACTS randomized clinical trial. JAMA., 2020, 324(7): 642-650

[15] Venkatesh B, Finfer S, Cohen J, et al. . Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med., 2018, 378(9): 797-808

[16] Welte T, Dellinger RP, Ebelt H, et al. . Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med., 2018, 44(4): 438-448

[17] Bai Z, Lai Y, Han K, et al. . Human albumin for adults with sepsis: an updated systematic review and meta-analysis of randomized controlled trials. Medicine., 2024, 103(52): e40983

[18] Li W, Zhao R, Liu S, et al. . High-dose vitamin C improves norepinephrine level in patients with septic shock: a single-center, prospective, randomized controlled trial. Medicine., 2024, 103(15): e37838

[19] Choudhary T, Upadhyaya P, Davis CM, et al. . Derivation and validation of generalized sepsis-induced acute respiratory failure phenotypes among critically ill patients: a retrospective study. Crit Care., 2024, 28(1): 321

[20] Lelubre C, Vincent JL. Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol., 2018, 14(7): 417-427

[21] Liu S, Wang Z, Su Y, et al. . A neuroanatomical basis for electroacupuncture to drive the vagal–adrenal axis. Nature., 2021, 598(7882): 641-645

[22] Liu F, Wang Y, Lyu K, et al. . Acupuncture and its ability to restore and maintain immune homeostasis. QJM., 2024, 117(3): 167-176

[23] Fang M, Lan Y, Li M, et al. . Electroacupuncture targeting the immune system to alleviate sepsis. Acupunct Herb Med., 2024, 4(1): 56-67

[24] Zhang Z, Li R, Chen Y, et al. . Integration of traditional, complementary, and alternative medicine with modern biomedicine: the scientization, evidence, and challenges for integration of traditional Chinese medicine. Acupunct Herb Med., 2024, 4(1): 68-78

[25] Liu S, Wang ZF, Su YS, et al. . Somatotopic organization and intensity dependence in driving distinct NPY-expressing sympathetic pathways by electroacupuncture. Neuron., 2020, 108(3): 436-450.e7

[26] Zhang J, Zhang B, Fauci AJ, et al. . The Rome consensus: Good clinical trials for traditional medicine. Integr Med Res., 2025, 14(3): 101211

[27] Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346 (jan08 15):e7586.

[28] Evans L, Rhodes A, Alhazzani W, et al. . Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med., 2021, 47(11): 1181-1247

[29] Vincent JL, Moreno R, Takala J, et al. . The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine (see contributors to the project in the appendix). Intensive Care Med., 1996, 22(7): 707-710

[30] Holliday EG, Weaver N, Barker D, et al. . Adapting clinical trials in health research: a guide for clinical researchers. Med J Aust., 2023, 218(10): 451-454

[31] Cui L, James Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics., 1999, 55(3): 853-857

[32] Bone RC, Balk RA, Cerra FB, et al. . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest., 1992, 101(6): 1644-1655

[33] Lambden S, Laterre PF, Levy MM, et al. . The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care., 2019, 23(1): 374

[34] Ulloa L, Quiroz-Gonzalez S, Torres-Rosas R. Nerve stimulation: immunomodulation and control of inflammation. Trends Mol Med., 2017, 23(12): 1103-1120

[35] Liu J, Dong S, Liu S. Aberrant parasympathetic responses in acupuncture therapy for restoring immune homeostasis. Acupunct Herb Med., 2023, 3(2): 69-75

[36] Birch S. A review and analysis of placebo treatments, placebo effects, and placebo controls in trials of medical procedures when sham is not inert. J Altern Complementary Med., 2006, 12(3): 303-310

[37] Linde K, Niemann K, Schneider A, et al. . How large are the nonspecific effects of acupuncture? A meta-analysis of randomized controlled trials. BMC Med., 2010, 8: 75

[38] Lund I, Lundeberg T. Are minimal, superficial or sham acupuncture procedures acceptable as inert placebo controls?. Acupunct Med., 2006, 24(1): 13-15

[39] Xu S, Yu L, Luo X, et al. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. BMJ. 2020:m697.

[40] Bhavani SV, Holder A, Miltz D, et al. . The precision resuscitation with crystalloids in sepsis (PRECISE) trial: a trial protocol. JAMA Netw Open., 2024, 7(9): e2434197

[41] Sevransky JE, Rothman RE, Hager DN, et al. . Effect of vitamin C, thiamine, and hydrocortisone on ventilator- and vasopressor-free days in patients with sepsis: the VICTAS randomized clinical trial. JAMA., 2021, 325(8): 742-750

[42] Daix T, Mathonnet A, Brakenridge S, et al. . Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Ann Intensive Care., 2023, 13(1): 17

[43] Marshall JC. Why have clinical trials in sepsis failed?. Trends Mol Med., 2014, 20(4): 195-203

[44] Liu F, Sheng S, Shao D, et al. . Targeting multiple mediators of sepsis using multifunctional tannic acid-Zn2+-gentamicin nanoparticles. Matter., 2021, 4(11): 3677-3695

[45] Wu Y, Wang L, Li Y, et al. . Immunotherapy in the context of sepsis-induced immunological dysregulation. Front Immunol., 2024, 15: 1391395

[46] Stanski NL, Wong HR. Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol., 2020, 16(1): 20-31

[47] Karnad DR, Bhadade R, Verma PK, et al. . Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med., 2014, 40(6): 830-838

[48] Wu J, Zhou L, Liu J, et al. . The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care., 2013, 17(1): R8

Funding

National Key Research and Development Program of China(2022YFC3500704)

China Primary Health Care Foundation(YLGX-ZZ-2020001)

RIGHTS & PERMISSIONS

The Author(s)

Just Accepted

This article has successfully passed peer review and final editorial review, and will soon enter typesetting, proofreading and other publishing processes. The currently displayed version is the accepted final manuscript. The officially published version will be updated with format, DOI and citation information upon launch. We recommend that you pay attention to subsequent journal notifications and preferentially cite the officially published version. Thank you for your support and cooperation.